8-K current report · filed Oct 29, 2026

Lilly (Eli) (LLY) 8-K Current Report: October 29, 2026

Item EX-99.1Item 2.02LLY overview

Short answer

Lilly (Eli) (LLY) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

Lilly (Eli) 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Results announced in Eli Lilly’s October 29, 2026 press release, Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $24.4B, up 39%, led by Mounjaro $10.7B and Zepbound $5.4B
  • Volume rose 53%, while realized prices fell 15%, highlighting strong demand but increasing pricing pressure
  • Reported EPS $7.22, up 16%, despite $4.57 per-share acquired IPR&D charges tied to business development
  • 2026 revenue guidance raised to $91B-$92B, while non-GAAP EPS guidance updated to $35.00-$36.00
  • FDA approvals expanded Mounjaro, Onswik, Inluriyo, and Jaypirca commercial opportunities; acquisitions broaden depression and autoimmune pipelines

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lilly (Eli) 8-K filings

Get the next LLY 8-K as it lands

Follow LLY for push alerts, or ask the research agent what this filing means.